Wuhan YZY Biopharma Co., Ltd. Class H had a revenue of 22.18M in the quarter ending Jun 30, 2025, with 0.00%. This bring the company's revenue in the last twelve months to 149.35M, Decreased 16.15%. In the fiscal year ending Dec 31, 2024, Wuhan YZY Biopharma Co., Ltd. Class H had annual revenue of 107.81M with 804.31% growth.